Welcome to our dedicated page for Biophytis SA news (Ticker: BPTS), a resource for investors and traders seeking the latest updates and insights on Biophytis SA stock.
Biophytis S.A. reports clinical-stage biotechnology developments centered on treatments for age-related diseases. Recurring updates focus on BIO101 (20-hydroxyecdysone), the company’s lead small-molecule drug candidate, across obesity, sarcopenia, Duchenne muscular dystrophy, and respiratory indications including severe forms of Covid-19.
Company news also covers regulatory submissions and authorizations for clinical studies, presentations of trial results, manufacturing scale-up for GMP-compliant supply, licensing and partnership activity in Latin America and Asia, and periodic financial results. The issuer’s American depositary security reflects parent-company announcements from Biophytis S.A. and its public-company disclosures.
Biophytis, a clinical-stage biotechnology company, is implementing a partnership strategy in obesity to develop therapeutics for age-related diseases. The company aims to find regional or global pharmaceutical partners to co-develop and commercialize BI0101 for the treatment of obesity and other indications. Biophytis is focused on driving scientific advancements to benefit obese patients worldwide and has a detailed action plan to achieve this goal.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.